medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 4

<< Back Next >>

Ann Hepatol 2017; 16 (4)

Hepatitis C Virus Infection and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis

Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P

Language: English
References: 35
Page: 514-520
PDF size: 149.40 Kb.


ABSTRACT

Background/Objectives. Hepatitis C virus (HCV) infection is one of the leading causes of cirrhosis. As a result of chronic inflammatory response to the virus, HCV-infected patients may be at a higher risk of venous thromboembolism (VTE). However, the data on this association is unclear. This systematic review and meta-analysis was conducted with the aims to summarize all available evidence. Material and methods. A literature search was performed using MEDLINE and EMBASE from inception to April 2016. Studies that reported relative risks, odd ratios, or hazard ratios comparing the risk of VTE among HCV-infected patients vs. subjects without HCV infection were included. Pooled risk ratios (RR) and 95% confidence interval (CI) were calculated using a random- effect, generic inverse variance method. Results. Three studies met our eligibility criteria and were included in analysis. The pooled RR of VTE in HCV-infected patients vs. subjects without HCV infection was 1.38 (95% CI, 1.08-1.77, I2 = 40%). Subgroup analysis showed that risk was increased for both pulmonary embolism (PE) and deep venous thrombosis (DVT) even though without adequate power to demonstrate statistical significance (Pooled RR of 1.34, 95% CI, 0.67-2.66 for PE and pooled RR 1.45, 95% CI, 0.93-2.77 for DVT). Conclusion. Our study demonstrated a significantly increased risk of VTE among HCV-infected patients. Further studies are required to clarify how this risk should be addressed in clinical practice.


REFERENCES

  1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42. doi: 10.1002/hep.26141.

  2. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud- Ratti V, Yamamoto AM, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C. Medicine (Baltimore) 2000; 79: 47-56.

  3. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002; 36: 1439-45. doi: 10.1053/ jhep.2002.37191.

  4. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123: 615-20.

  5. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008; 28: 370-2. doi: 10.1161/ATVBAHA.108.162545.

  6. Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 2010; 137: 1145-9. doi: 10.1378/chest.09-2177.

  7. Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol 2010; 56: 1-7. doi: 10.1016/ j.jacc.2010.01.057.

  8. Ocak G, Vossen CY, Verduijn M, Dekker FW, Rosendaal FR, Cannegieter SC, Lijfering WM. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J Thromb Haemost 2013; 11: 116-23. doi: 10.1111/jth.12043.

  9. Ungprasert P, Srivali N, Wijarnpreecha K, Charoenpong P, Knight EL. Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and metaanalysis. Rheumatology (Oxford) 2015; 54: 736-42. doi: 10.1093/rheumatology/keu408.

  10. Saghazadeh A, Rezaei N. Inflammation as a cause of venous thromboembolism. Crit Rev Oncol Hematol 2016; 99: 272-85. doi: 10.1016/j.critrevonc.2016.01.007.

  11. Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie 2010; 30: 5-6, 8-9.

  12. Alkim H, Koksal AR, Boga S, Sen I, Alkim C. Etiopathogenesis, Prevention, and Treatment of Thromboembolism in Inflammatory Bowel Disease. Clin Appl Thromb Hemost 2016. doi: 10.1177/1076029616632906.

  13. Avina-Zubieta JA, Vostretsova K, De Vera MA, Sayre EC, Choi HK. The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population- based study. Semin Arthritis Rheum 2015; 45: 195- 201. doi: 10.1016/j.semarthrit.2015.05.008.

  14. Ungprasert P, Sanguankeo A. Risk of venous thromboembolism in patients with idiopathic inflammatory myositis: a systematic review and meta-analysis. Rheumatol Int 2014; 34: 1455-8. doi: 10.1007/s00296-014-3023-1.

  15. Ungprasert P, Sanguankeo A, Upala S, Suksaranjit P. Psoriasis and risk of venous thromboembolism: a systematic re view and meta-analysis. QJM 2014; 107: 793-7. doi: 10.1093/qjmed/hcu073.

  16. Ungprasert P, Srivali N, Spanuchart I, Thongprayoon C, Knight EL. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2014; 33: 297-304. doi: 10.1007/s10067- 014-2492-7.

  17. Ungprasert P, Wijarnpreecha K, Tanratana P. Risk of venous thromboembolism in patients with celiac disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2015. doi: 10.1111/jgh.13282.

  18. Ahmed S MV, Vendeti N, Ann Phang K, Su Y, Kim H, Mast T, Nancy S. Risk of venous thromboembolism (VTE) in patients with chronic hepatitis C (CHC). Pharmacoepidemiol Drug Saf 2012; 21: 94.

  19. Best MJ, Buller LT, Klika AK, Barsoum WK. Increase in perioperative complications following primary total hip and knee arthroplasty in patients with hepatitis C without cirrhosis. J Arthroplasty 2015; 30: 663-8. doi: 10.1016/ j.arth.2014.11.013.

  20. Enger C, Forssen UM, Bennett D, Theodore D, Shantakumar S, McAfee A. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Adv Ther 2014; 31: 891-903. doi: 10.1007/s12325- 014-0138-4.

  21. Galli L, Gerdes VE, Guasti L, Squizzato A. Thrombosis Associated with Viral Hepatitis. J Clin Transl Hepatol 2014; 2: 234-9. doi: 10.14218/JCTH.2014.00031.

  22. Wang CC, Chang CT, Lin CL, Lin IC, Kao CH. Hepatitis C Virus Infection Associated With an Increased Risk of Deep Vein Thrombosis: A Population-Based Cohort Study. Medicine (Baltimore) 2015; 94: e1585. doi: 10.1097/ MD.0000000000001585.

  23. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-5. doi: 10.1007/s10654-010-9491-z.

  24. Herzog R, Alvarez-Pasquin MJ, Diaz C, Del Barrio JL, Estrada JM, Gil A. Are healthcare workers’ intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health 2013; 13: 154. doi: 10.1186/ 1471-2458-13-154.

  25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.

  26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60. doi: 10.1136/bmj.327.7414.557.

  27. Ambrosino P, Tarantino L, Criscuolo L, Nasto A, Celentano A, Di Minno MN. The risk of venous thromboembolism in patients with hepatitis C. A systematic review and meta-analysis. Thromb Haemost 2016; 116: 958-966. doi: 10.1160/ TH16-03-0185.

  28. RostamiJalilian M. OGM, Kassaeian N. Relationship of Hepatitis B and C with Deep Vein Thrombosis in I.V Drug Abusers. J Mil Med 2006; 8: 78-81.

  29. El Bokl MA, Shawky A, Riad GS, Abdel Fattah HS, Shalaby H, Nady A, Khattab D. Procoagulant versus anticoagulant factors in cirrhotic patients. Arab J Gastroenterol 2014; 15: 123-9. doi: 10.1016/j.ajg.2014.08.003.

  30. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009; 48: 11-22. doi: 10.1093/rheumatology/ken395.

  31. Samad F, Ruf W. Inflammation, obesity, and thrombosis. Blood 2013; 122: 3415-22. doi: 10.1182/blood-2013-05- 427708.

  32. Bartoloni E, Shoenfeld Y, Gerli R. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res (Hoboken) 2011; 63: 178-83. doi: 10.1002/acr.20322.

  33. Biasillo G, Leo M, Della Bona R, Biasucci LM. Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med 2010; 5: 225-33. doi: 10.1007/s11739-010-0361-1.

  34. Ramos-Casals M, Munoz S, Medina F, Jara LJ, Rosas J, Calvo- Alen J, Brito-Zeron P, et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009; 36: 1442-8. doi: 10.3899/jrheum.080874.

  35. Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int 2016; 10: 415-23. doi: 10.1007/s12072-015-9684-3.




2020     |     www.medigraphic.com